Skip to main content
. Author manuscript; available in PMC: 2014 Sep 15.
Published in final edited form as: Biochem Pharmacol. 2013 Aug 5;86(6):824–835. doi: 10.1016/j.bcp.2013.07.023

Figure 3. Compound 1 activates PXR-regulated CYP3A4 promoter.

Figure 3

HepG2 transiently transfected with hPXR, CYP3A4-luc, and CMV-Renilla were treated for 24 h with indicated concentrations of rifampicin or compound 1 prior to luciferase assay.